

## Supporting Information

### Conformationally Constrained Peptidomimetic Inhibitors of Signal Transducer and Activator of Transcription 3.

Pijus K. Mandal,<sup>1\*\*</sup> Donald Limbrick,<sup>5\*\*</sup> David R. Coleman IV,<sup>4</sup> Zhiyong Ren,<sup>2</sup> J. Sanderson Birtwistle,<sup>1</sup> Chiyi Xiong,<sup>3</sup> Xiaomin Chen,<sup>2</sup> James M. Briggs,<sup>5</sup> John S. McMurray<sup>1\*</sup>

#### Table of Contents

General Procedures.....	S2 – S4
Table S1, Mass Spectral characterization of final products <b>5-35</b> .....	S5 – S6
HPLC chromatograms of final products <b>5-35</b> .....	S7 – S37
NMR characterization of compound <b>45</b> .....	S38 – S40
NMR characterization of compound <b>47</b> .....	S41 – S43

## General Procedures

*N*<sup>α</sup>-protected amino acids were purchased from Advanced Chemtech, NovaBiochem, ChemImpex, or AnaSpec. HOBt was from ChemImpex. Rink amide resin from Advanced Chemtech, loaded between 0.7 mmol/g or 1.2 mmol/g. Anhydrous DMF for amino acid solutions was from Aldrich. Other solvents were reagent grade and were used without further purification. NMR spectra were obtained on either a Bruker DPX 300 MHz spectrometer or a Bruker DRX 500 MHz spectrometer. Fluorescence polarization assays were carried out as described in Coleman et al (2005).

**General Procedure for the synthesis of peptides and peptidomimetics.** Solid phase syntheses were carried out manually using commercially available Rink resin. Resin, 0.1 – 0.2 gm, was placed in a manual reactor and swollen and washed with 5 × 10 mL of DMF/CH<sub>2</sub>Cl<sub>2</sub>. Fmoc groups were removed with 3 × 6 mL of 20% piperidine/DMF for 5 min each. For coupling, three-fold excesses of Fmoc-amino acids, DIC, and HOBt were used in 8-10 mL of DMF/CH<sub>2</sub>Cl<sub>2</sub> and were allowed to proceed until resin samples tested negative with ninhydrin tests. For Fmoc-Haic and its analogues, stereoisomers of Fmoc-ABN, and phosphorylated cinnamic acid derivatives, couplings were performed with 1.5 equivalents each of acid, DIC and HOBt in DMF/CH<sub>2</sub>Cl<sub>2</sub> overnight. After coupling and deprotection steps, resins were washed with 3 × 10 mL of DMF/CH<sub>2</sub>Cl<sub>2</sub>. On completion of the peptide chain, resins were washed with CH<sub>2</sub>Cl<sub>2</sub> 3 × 10 mL and were treated with TFA:TIS:H<sub>2</sub>O (95:2.5:2.5) (Pearson et al., 1989) (3 × 5 mL) for 15 min each. The combined filtrates sat at rt for 1-2 hr and the volumes were reduced in vacuo. Peptides were precipitated in ice cold Et<sub>2</sub>O, collected by centrifugation, and washed 2 × more with the same solvent and centrifuged. After drying, peptides were purified by reverse phase HPLC on a Rainin Rabbit HPLC or a Varian HPLC using a Vydac 2.5 × 25 cm C18

Peptide and Protein column or a Phenomenex Luna C18 2.5 × 25 cm column. Gradients of ACN in H<sub>2</sub>O (both containing 0.1% TFA) or ACN in 0.01 M NH<sub>4</sub>OAc (pH 6.5) at 10 mL/min were employed. Peptides were tested for purity by reverse phase HPLC on a Hewlett Packard 1090 HPLC or an Agilent 1100 HPLC using a Vydac 4.6 × 250 mm C18 peptide/protein column or a Phenomenex Luna 4.6 × 250 mm C18 in two systems, one with 0.1% TFA in both H<sub>2</sub>O and ACN and the other with a gradient of ACN in 0.01 M NH<sub>4</sub>OAc, pH6.5. Gradients were 0 – 40% ACN/30 min. Peptides were dried in vacuo over P<sub>2</sub>O<sub>5</sub> at 37° for 24 hr prior to use.

**General procedure for the phosphorylation of resin-bound peptides. Synthesis of Ac-Tic(OPO<sub>3</sub>H<sub>2</sub>)-Leu-Pro-Gln-Thr-NH<sub>2</sub>, 9**

**Solid phase synthesis of Fmoc-Tic(OH)-Leu-Pro-Gln(Trt)-Thr(OtBu)-NHRink Resin** was carried out manually, with 0.20 gm of Rink resin (1.2 mmol/g) following the solid phase peptide synthesis methodology described above. After assembly of the amino acid chain, the resin was washed in dry CH<sub>2</sub>Cl<sub>2</sub> and suspended in 10 mL of the same solvent. Dibenzyl-*N,N*-diisopropylphosphoramidite (0.4 mL, 1.2mmol) and tetrazole (0.2 g, 2.4mmol) were added and agitated gently with N<sub>2</sub> for 3 hr. The resin was drained, washed with DMF (2 × 5mL), and treated with 5-6 M *tert*-butylhydroperoxide in decane (0.5 mL, 2.5 mmol) diluted with 5mL of DMF, for 1h. The resin was washed with DMF (3 × 5mL) and the Fmoc group was removed as above. After washing the peptide was acetylated with acetic anhydride (1 mL) and 0.2mL of DIPEA in 5 mL of DMF/CH<sub>2</sub>Cl<sub>2</sub>. On completion of the coupling the resin was drained and washed with DMF/CH<sub>2</sub>Cl<sub>2</sub> (3 ×) followed by CH<sub>2</sub>Cl<sub>2</sub> (3 ×). The phosphorylated peptide was cleaved from the resin by treatment of TFA:TIS:H<sub>2</sub>O (95:2.5:2.5) as described above. After drying the solid crude peptide (83mg) was purified by reverse phase HPLC on a Phenomenex

Luna 2.5 × 20 gm column using a gradient of ACN in H<sub>2</sub>O (both containing 0.1% TFA) giving 36 mg of product. ESI-MS Calcd (M+H) for C<sub>32</sub>H<sub>49</sub>N<sub>7</sub>O<sub>12</sub>P : 754.3177, found: 754.1904.

## REFERENCES

Coleman, IV, D.R.; Ren, R.; Mandal, P.K.; Cameron, A.G.; Dyer, G.A.; Muranjan, S.; Chen, X.; McMurray, J.S. Investigation of the binding determinants of phosphopeptides targeted to the SH2 domain of Stat3. Development of a high affinity peptide inhibitor. *J. Med. Chem.* **2005**, *48*, 6661-6670.



Pearson, D.A.; Blanchette, M.; Baker, M.L.; Guindon, C.A Trialkylsilanes as scavengers for the trifluoroacetic acid deblocking of protecting groups in peptide synthesis *Tetrahedron Lett.* **1989**, *30*, 2739-2742.



Table S1. Mass spectral analysis of phosphopeptide inhibitors of Stat3.

	Compound	M+H calc	M+H Found
<b>5</b>	pCinn-Leu-Pro-Gln-Thr-NH <sub>2</sub>	683.2806	683.3
<b>6</b>	pInd-Leu-Pro-Gln-Thr-NH <sub>2</sub>	696.2758	696.3
<b>7</b>	2-phospho-7-carbonyl-naphthyl-Leu-Pro-Gln-Thr-NH <sub>2</sub>	707.2806	707.26
<b>8</b>	6-phosphoindole-3-acetic acid-Leu-Pro-Gln-Thr-NH <sub>2</sub>	710.2915	710.30
<b>9</b>	N-Ac-7-phosphoryloxyTic Leu-Pro-Gln-Thr-NH <sub>2</sub>	754.1904	754.3177
<b>10</b>	3-pCinn-Leu-Pro-Gln-Thr-NH <sub>2</sub>	683.2806	683.1765
<b>11</b>	Ac-pTyr-(3 <i>S</i> ,6 <i>S</i> ,9 <i>S</i> )-ABN-Gln-Thr-NH <sub>2</sub>	712.2707	712.2700
<b>12</b>	Ac-pTyr-(3 <i>S</i> ,6 <i>R</i> ,9 <i>R</i> )-ABN-Gln-Thr-NH <sub>2</sub>	712.2707	712.2700
<b>13</b>	Ac-pTyr-Haic-Gln-Thr-NH <sub>2</sub>	760.2707	760.30
<b>14</b>	Ac-pTyr-( <i>R</i> )Haic-Gln-Thr-NH <sub>2</sub>	760.2707	760.28
<b>15</b>	Ac-pTyr-Leu-Indoline-Gln-Thr-NH <sub>2</sub>	790.3177	790.5
<b>16</b>	pHcinn-Haic-Gln-Thr-NH <sub>2</sub>	703.2493	703.3
<b>17</b>	pCinn-Leu-Pro-Gln-NHBn	671.2720	671.3500
<b>18</b>	pCinn-(3 <i>S</i> ,6 <i>S</i> ,9 <i>S</i> )-ABN-Gln-NHBn	642.2329	642.1000
<b>19</b>	pCinn-(3 <i>S</i> ,6 <i>R</i> ,9 <i>S</i> )-ABN-Gln-NHBn	642.2329	642.2000
<b>20</b>	pCinn-(3 <i>S</i> ,6 <i>R</i> ,9 <i>R</i> )-ABN-Gln-NHBn	642.2329	642.1000


<b>21</b>	pCinn-Haic-Gln-NHBn	690.2329	690.1551
<b>22</b>	pCinn-ΔHaic-Gln-NHBn	688.2094	688.2184
<b>23</b>	pInd-Haic-Gln-NHBn	703.2203	703.23
<b>24</b>	pCinn-Haic-Gaba	557.1723	557.20
<b>25</b>	pCinn-Haic-pyrrolidine acetamide	583.1880	583.1000
<b>26</b>	pCinn-Haic-Gln-OH	601.1700	601.0845
<b>27</b>	pCinn-Haic-Gln-OMe	615.1856	615.1725
<b>28</b>	pCinn-Haic-Gln-NH <sub>2</sub>	600.1859	600.1233
<b>29</b>	pCinn-Haic-Gln-NHMe	614.2016	614.1485
<b>30</b>	pCinn-Haic-Gln-NHiPr	642.2329	642.2718
<b>31</b>	pCinn-Haic-NH <sub>2</sub>	472.1195	472.1324
<b>32</b>	pCinn-Haic-Ala-NH <sub>2</sub>	543.1567	543.1830
<b>33</b>	pCinn-Haic-Nle-NH <sub>2</sub>	585.2036	585.2200
<b>34</b>	pCinn-Haic-Met(O)-NH <sub>2</sub>	619.1628	619.0628
<b>35</b>	pCinn-Haic-Met(O <sub>2</sub> )-NH <sub>2</sub>	635.1577	635.0473

---











DAD1 A, Sig=230.4 Ref=450.80 (071-0201.D)





8 6-phosphoindole-3-acetic acid-Leu-Pro-Gln-Thr-NH2


DAD1 B, Sig=275.4 Ref=450.80 (071-0201.D)




9 N-Ac-7-phosphoryloxyTic Leu-Pro-Gln-Thr-NH<sub>2</sub>











DAD1 A, Sig=275,4 Ref=550,100 (DKIDDY032-0501.D)




13 Ac-pTyr-Haic-Gln-Thr-NH<sub>2</sub>


DAD1 B, Sig=230,16 Ref=550,100 (DKIDDY032-0501.D)



S15









15 Ac-pTyr-Leu-Ind-Haic-Gln-Thr-NH<sub>2</sub>

S17


DAD1 A, Sig=230.4 Ref=450.80 (070-0201.D)



DAD1 B, Sig=275.4 Ref=450.80 (070-0201.D)




DAD1 A, Sig=275,4 Ref=550,100 (061-0101.D)




17 pCinn-Leu-Pro-Gln-NH<sub>2</sub>


DAD1 B, Sig=230,16 Ref=550,100 (061-0101.D)




S19



S20




DAD1 A, Sig=275,4 Ref=550,100 (088-1901.D)




19 pCinn-(3S,6R,9S)-ABN-Gln-NHBn

DAD1 B, Sig=230,16 Ref=550,100 (088-1901.D)




S21

DAD1 A, Sig=275,4 Ref=550,100 (089-0901.D)




20 pCinn-(3S,6R,9R)-ABN-Gln-NHBn

DAD1 B, Sig=230,16 Ref=550,100 (089-0901.D)




DAD1 A, Sig=275,4 Ref=550,100 (023-0201.D)




**21** pCinn-Haic-Gln-NHBr

DAD1 B, Sig=230,16 Ref=550,100 (023-0201.D)




S23

DAD1 A, Sig=275,4 Ref=550,100 (043-2601.D)



22 pCinn-ΔHaic-Gln-NHBn


DAD1 B, Sig=230,16 Ref=550,100 (043-2601.D)




424




DAIPIE INQUIRY  
AmmAc (MG01H)



DAD1 A, Sig=230,4 Ref=450,80 (024-0901.D)




DAD1 B, Sig=275,4 Ref=450,80 (024-0901.D)




DAD1 A, Sig=275,4 Ref=550,100 (032-1401.D)

p-Cinn-Haic-Pyrrolidine  
AmuAc/MSOH




25  
pCinn-Haic-pyrrolidine acetamide


DAD1 B, Sig=230,16 Ref=550,100 (032-1401.D)



S27




DAD1 A, Sig=275,4 Ref=550,100 (023-0701.D)





27 pCinn-Haic-Gln-OMe

DAD1 B, Sig=230,16 Ref=550,100 (023-0701.D)




S29






DAD1 A, Sig=275.4 Ref=550.100 (024-1201.D)




**30**  
pCinn-Haic-Gln-NH/Pr


DAD1 B, Sig=230.16 Ref=550.100 (024-1201.D)




232









DAD1 A, Sig=230.4 Ref=450.80 (071-0301.D)




DAD1 B, Sig=275.4 Ref=450.80 (071-0301.D)






DAD1 A, Sig=275.4 Ref=550.100 (062-0201.D)




35 pCinn-Haic-Met(O<sub>2</sub>)-NH<sub>2</sub>

DAD1 B, Sig=230.16 Ref=550.100 (062-0201.D)



(R)-4-Oxo-5-(Fmoc-amino)-1,2,4,5,6,7-hexahydro-2-azepino-indole-2-carboxylic acid



45

#	Chemical Shift (ppm)
1	1.958
2	2.006
3	2.021
4	2.043
5	2.465
6	2.471
7	2.477
8	2.945
9	2.983
10	3.380
11	3.419
12	3.436
13	3.475
14	3.986
15	4.010
16	4.185
17	4.208
18	4.229
19	4.250
20	4.280
21	4.299
22	4.863
23	4.876
24	4.900
25	4.914
26	6.887
27	6.911
28	6.936
29	6.983
30	7.007
31	7.044
32	7.068
33	7.280
34	7.304
35	7.328
36	7.366
37	7.390
38	7.414
39	7.686
40	7.711
41	7.746
42	7.852
43	7.876

Current Data Parameters  
 NAME JSB-II-108-F15-65  
 EXPNO 4  
 PROCNO 1

F2 - Acquisition Parameters


Date\_ 20080826  
 Time 13.42  
 INSTRUM spect  
 PROBD 5 mm QNP 1H/19  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 6172.839 Hz  
 FIDRES 0.094190 Hz  
 AQ 5.3084660 sec  
 RG 256  
 DW 81.000 usec  
 DE 6.00 usec  
 TE 683.2 K  
 D1 1.00000000 sec  
 TD0 1

CHANNEL f1

NUC1 1H  
 P1 10.25 usec  
 PL1 -1.00 dB  
 SF01 300.1318534 MHz

F2 - Processing parameters

SI 32768  
 SF 300.1300011 MHz  
 WDM EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00











(S0-9-OXO-8- (FMOC-AMONO) -2, 8, 9, 9a-TETRAHYDRO-BENZO-AZULENE-1-CARBOXYLIC ACID

8.149
8.132
7.891
7.876
7.755
7.738
7.720
7.423
7.408
7.393
7.344
7.330
7.315
7.295
7.281
7.233
7.217
7.100
7.085
6.810
6.806
6.790
6.786
5.726
5.717
5.706
5.104
5.102
5.083
5.080
4.341
4.327
4.307
4.293
4.273
4.261
4.247
4.233
3.087
3.054
2.483
2.480
2.477
1.966



47




Current Data Parameters  
 NAME JSB-IT-101-F28-30  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20080520  
 Time 14.26  
 INSTRUM spect  
 PROBHD 5 mm TXI 1H/D-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 16  
 DS 2  
 SWH 10330.578 Hz  
 FIDRES 0.157632 Hz  
 AQ 3.1720407 sec  
 RG 64  
 DW 48.400 usec  
 DE 7.50 usec  
 TE 301.2 K  
 D1 1.00000000 sec  
 TD0 1


===== CHANNEL F1 =====  
 NUC1 1H  
 P1 8.50 usec  
 PL1 -2.00 dB  
 SFO1 500.1330885 MHz  
 F2 - Processing Parameters  
 SI 32768  
 SF 500.1300051 MHz  
 MDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 ppm



172.53  
166.40  
156.53  
144.34  
144.22  
141.23  
139.15  
132.80  
128.29  
128.13  
127.59  
126.31  
125.76  
125.71  
125.06  
124.02  
120.61

47



66.33  
61.83  
60.22  
54.59  
47.10  
40.51  
40.34  
40.27  
40.18  
40.01  
39.84  
39.68  
39.51  
32.58  
14.56

Current Data Parameters  
NAME JSB-IT-101-F28-30  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20080520  
Time 14.41

INSTRUM spect  
PROBHD 5 mm TXI 1H/D-  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 956  
DS 4  
SWH 30030.029 Hz  
FIDRES 0.458222 Hz  
AQ 1.0912410 sec  
RG 14596.5  
DW 16.650 usec  
DE 7.50 usec  
TE 301.2 K  
D1 2.00000000 sec  
d11 0.03000000 sec  
DELTA 1.89999998 sec  
TD0 1

CHANNEL f1 =====  
NUC1 13C  
P1 12.00 usec  
PL1 -5.50 dB  
SFO1 125.7703643 MHz

CHANNEL f2 =====  
CPDPRG2 waltz16  
NUC2 1H  
PCPD2 90.00 usec  
PL2 -2.00 dB  
PL12 18.50 dB  
PL13 20.00 dB  
SFO2 500.1320005 MHz

F2 - Processing parameters  
SI 32768  
SF 125.7577890 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.00



JSB-II-111-F28-30 7 1 /opt/rospin mcmurray

